Nat Turner built Flatiron Health after his cousin's leukemia journey led him to focus on fixing how oncology data is collected and used, developing a distinctive data-first approach that structured real-world clinical data from cancer centers to power both patient care and drug development. He maintains an unusual dual identity as both a leading health-tech founder (Flatiron's $1.9B acquisition by Roche) and CEO of Collectors (parent of PSA), making him a genuine power user of grading and marketplace products while serving as an active early-stage investor at Operator Partners. Nat Turner built Flatiron Health after his cousin's leukemia journey led him to focus on fixing how oncology data is collected and used, developing a distinctive data-first approach that structured real-world clinical data from cancer centers to power both patient care and drug development. He maintains an unusual dual identity as both a leading health-tech founder (Flatiron's $1.9B acquisition by Roche) and CEO of Collectors (parent of PSA), making him a genuine power user of grading and marketplace products while serving as an active early-stage investor at Operator Partners.